December 1 2020 CBPP Spotlight | Case-Based Peer Perspectives Spotlight Live

Exploring Options for First- and Second-Line Therapies in cSCC

December 31, 2020

Clinical Articles

The plan of treatment for a 69-year-old patient with poorly differentiated, infiltrative, cutaneous squamous cell carcinoma was the topic of discussion among Dan Paul Zandberg, MD, and other clinicians in attendance during a Targeted Oncology Case-Based Peer Perspectives event.

Expert Expands on Treatment Choices in Patients With Genomic Aberrations in CLL

December 30, 2020

Clinical Articles

During a Targeted Oncology Case-Based Peer Perspective event, Jonathon B. Cohen, MD, MS, discussed therapeutic options for a 71-year-old patients with chronic lymphocytic leukemia and a genomic aberration.

Deciding on an Agent for Prostate Cancer Involves Careful Consideration of Prior Therapy

December 28, 2020

Anthony A. Meluch, MD, medical oncologist, Tennessee Oncology, discussed treatment options for high-risk adenocarcinoma of the prostate based on the case of a 75-year-old patient during a Targeted Oncology Case-Based Peer Perspectives event.

New Evidence Supports Targeted Therapies in Early-Stage NSCLC With EGFR Mutations

December 16, 2020

Clinical Articles

During a Targeted Oncology Case Based Peer Perspectives event Karen L. Kelly, MD, discussed molecular testing guidelines and testing execution for early-stage non–small cell lung cancer as well as the research supporting the use of targeted therapies for treatment.

Therapy Options Compared for the Treatment of Recurrent DLBCL

December 02, 2020

Clinical Articles

Loretta J. Nastoupil, MD, discussed the use of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma during a Targeted Oncology Case Based Peer Perspectives event.

Tafasitamab/Lenalidomide Combo Stands Out for Patients With Relapsed/Refractory DLBCL

December 01, 2020

Clinical Articles

During a Targeted Oncology Case Base Peer Perspective event, Ian W. Flinn, MD, PhD, compares the combination of tafasitamab-cxix plus lenalidomide, and selinexor as treatment of relapsed or refractory diffuse large B-cell lymphoma to other other available regimens.